Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2024

Report ID: 1871003 | Published Date: Jan 2025 | No. of Page: 94 | Base Year: 2024 | Rating: 4.3 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Overview
    1.1 Product Overview and Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
    1.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
        1.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 Exenatied
        1.2.3 Liraglutide
        1.2.4 Lixisenatide
        1.2.5 Albiglutide
        1.2.6 Dulaglutide
    1.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
        1.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Comparison by Application: (2022-2028)
        1.3.2 Hospital
        1.3.3 Pharmacy
    1.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Estimates and Forecasts
        1.4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2017-2028
        1.4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2017-2028
        1.4.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region: 2017 Versus 2021 Versus 2028
2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competition by Manufacturers
    2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Sites, Area Served, Product Type
    2.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
        2.5.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
        2.5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glucagon-like peptide 1 (GLP-1)-based Therapies Retrospective Market Scenario by Region
    3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
        3.3.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
        3.3.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country
        3.3.3 United States
        3.3.4 Canada
    3.4 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
        3.4.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
        3.4.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Region
        3.5.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
        3.5.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 China Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
    3.6 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
        3.6.1 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
        3.6.2 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Facts & Figures by Country
        3.7.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
        3.7.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Historic Market Analysis by Type
    4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022)
    4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2022)
    4.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2017-2022)
5 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Historic Market Analysis by Application
    5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022)
    5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2022)
    5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Novo Nordisk
        6.1.1 Novo Nordisk Corporation Information
        6.1.2 Novo Nordisk Description and Business Overview
        6.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
        6.1.5 Novo Nordisk Recent Developments/Updates
    6.2 AstraZeneca
        6.2.1 AstraZeneca Corporation Information
        6.2.2 AstraZeneca Description and Business Overview
        6.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
        6.2.5 AstraZeneca Recent Developments/Updates
    6.3 Eli Lily
        6.3.1 Eli Lily Corporation Information
        6.3.2 Eli Lily Description and Business Overview
        6.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
        6.3.5 Eli Lily Recent Developments/Updates
    6.4 GSK
        6.4.1 GSK Corporation Information
        6.4.2 GSK Description and Business Overview
        6.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
        6.4.5 GSK Recent Developments/Updates
    6.5 Sanofi
        6.5.1 Sanofi Corporation Information
        6.5.2 Sanofi Description and Business Overview
        6.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
        6.5.5 Sanofi Recent Developments/Updates
    6.6 Bristol-Myers Squibb
        6.6.1 Bristol-Myers Squibb Corporation Information
        6.6.2 Bristol-Myers Squibb Description and Business Overview
        6.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolio
        6.6.5 Bristol-Myers Squibb Recent Developments/Updates
7 Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Cost Analysis
    7.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
    7.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List
    8.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Customers
9 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Dynamics
    9.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Trends
    9.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
    9.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
    9.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints
10 Global Market Forecast
    10.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2023-2028)
    10.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Glucagon-like peptide 1 (GLP-1)-based Therapies by Application (2023-2028)
    10.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Glucagon-like peptide 1 (GLP-1)-based Therapies by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables
    Table 1. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate Comparison by Type (2022-2028) & (Units) & (US$ Million)
    Table 2. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate Comparison by Application (2022-2028) & (Units) & (US$ Million)
    Table 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units) of Key Manufacturers (2017-2022)
    Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (US$/Unit) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Sites and Area Served
    Table 11. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2022) & (Units)
    Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2017-2022)
    Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2017-2022)
    Table 19. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
    Table 20. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2017-2022)
    Table 21. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2017-2022)
    Table 23. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
    Table 24. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2017-2022)
    Table 25. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2022) & (Units)
    Table 28. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
    Table 32. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2017-2022)
    Table 33. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
    Table 36. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2017-2022)
    Table 39. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units)
    Table 40. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022)
    Table 41. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Type (2017-2022)
    Table 43. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2017-2022) & (US$/Unit)
    Table 44. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units) by Application (2017-2022)
    Table 45. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022)
    Table 46. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Application (2017-2022)
    Table 48. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Application (2017-2022) & (US$/Unit)
    Table 49. Novo Nordisk Corporation Information
    Table 50. Novo Nordisk Description and Business Overview
    Table 51. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 52. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product
    Table 53. Novo Nordisk Recent Developments/Updates
    Table 54. AstraZeneca Corporation Information
    Table 55. AstraZeneca Description and Business Overview
    Table 56. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 57. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product
    Table 58. AstraZeneca Recent Developments/Updates
    Table 59. Eli Lily Corporation Information
    Table 60. Eli Lily Description and Business Overview
    Table 61. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 62. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product
    Table 63. Eli Lily Recent Developments/Updates
    Table 64. GSK Corporation Information
    Table 65. GSK Description and Business Overview
    Table 66. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 67. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product
    Table 68. GSK Recent Developments/Updates
    Table 69. Sanofi Corporation Information
    Table 70. Sanofi Description and Business Overview
    Table 71. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 72. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product
    Table 73. Sanofi Recent Developments/Updates
    Table 74. Bristol-Myers Squibb Corporation Information
    Table 75. Bristol-Myers Squibb Description and Business Overview
    Table 76. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 77. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product
    Table 78. Bristol-Myers Squibb Recent Developments/Updates
    Table 79. Production Base and Market Concentration Rate of Raw Material
    Table 80. Key Suppliers of Raw Materials
    Table 81. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List
    Table 82. Glucagon-like peptide 1 (GLP-1)-based Therapies Customers List
    Table 83. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Trends
    Table 84. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
    Table 85. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
    Table 86. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints
    Table 87. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2023-2028) & (Units)
    Table 88. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2023-2028)
    Table 89. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 90. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Type (2023-2028)
    Table 91. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2023-2028) & (Units)
    Table 92. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Application (2023-2028)
    Table 93. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 94. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Application (2023-2028)
    Table 95. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2023-2028) & (Units)
    Table 96. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Region (2023-2028)
    Table 97. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 98. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Region (2023-2028)
    Table 99. Research Programs/Design for This Report
    Table 100. Key Data Information from Secondary Sources
    Table 101. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
    Figure 2. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type in 2021 & 2028
    Figure 3. Exenatied Product Picture
    Figure 4. Liraglutide Product Picture
    Figure 5. Lixisenatide Product Picture
    Figure 6. Albiglutide Product Picture
    Figure 7. Dulaglutide Product Picture
    Figure 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2021 & 2028
    Figure 9. Hospital
    Figure 10. Pharmacy
    Figure 11. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (2017-2028) & (US$ Million)
    Figure 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (2017-2028) & (Units)
    Figure 14. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2021
    Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2021
    Figure 16. The Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players: Market Share by Revenue in 2021
    Figure 17. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2017-2022)
    Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2021
    Figure 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2017-2022)
    Figure 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region in 2021
    Figure 22. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 23. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. China Taiwan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Indonesia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Thailand Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Malaysia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2017-2022)
    Figure 45. Manufacturing Cost Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies
    Figure 46. Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
    Figure 47. Glucagon-like peptide 1 (GLP-1)-based Therapies Industrial Chain Analysis
    Figure 48. Channels of Distribution
    Figure 49. Distributors Profiles
    Figure 50. Bottom-up and Top-down Approaches for This Report
    Figure 51. Data Triangulation
    Figure 52. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Frequently Asked Questions
Glucagon-like peptide 1 (GLP-1)-based Therapies report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Glucagon-like peptide 1 (GLP-1)-based Therapies report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Glucagon-like peptide 1 (GLP-1)-based Therapies report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports